FDA Grants Priority Review to Genentechs Tecentriq in Combination with Abraxane for the ...
FDA Grants Priority Review to Genentech’s Tecentriq in Combination with Abraxane for the ...
– If approved, this Tecentriqcombination would be the first cancer immunotherapy regimen for the treatment of PD-L1-positive, metastatic triple-negative breast cancer –
Read more...
More From BioPortfolio on "FDA Grants Priority Review to Genentech’s Tecentriq in Combination with Abraxane for the ..."